Gilead Sciences' CEO John Milligan, PhD, will step down from his role by the end of the year, the Wall Street Journal reported.
Here are three key details:
1. Dr. Milligan will also step down from the board of directors once his replacement is found.
2. Hs spent 28 years at Gilead and served as CEO for the past two years.
3. Dr. Milligan's departure comes as the company struggles with falling sales and profit. Gilead's profits were $5.65 billion in the second quarter of 2018, down 21 percent compared to $7.1 billion in 2017, according to MarketWatch.